Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

NCT00083694 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Leukemia

Interventions

DRUG: Thalidomide

Sponsor

University of Arkansas

Collaborators

[object Object]